Peter Besler

Last updated

Peter Besler (born October 5, 1963) is an investment advisor and author residing in Toronto, Ontario, Canada. Born in Waterloo, Ontario, Besler is known for raising public funds in order to finance Canadian companies conducting research into the treatment of serious and terminal illnesses. Since 1986, his efforts have benefited numerous biotechnology and medical research companies conducting pre-clinical and phase I, II, and III human clinical trials. [1]

Contents

Biography

Besler was as a co-op chemistry student at University of Waterloo. In 1982, he grew concerned that scientific research in Canada was inadequately funded. [2] He co-led the Progressive Conservative Party Campus Youth in 1983. [3] Switching his area of study, he graduated with a degree in Economics in 1986. Shortly after graduation, he moved to Toronto and studied investment banking under Gerszon Taichman. [4] In 1994, Besler traveled to China with the purpose of establishing in-vitro fertilization clinics with researchers from Cornell University. [5] In 2001, he became aware of promising research conducted by Dr. Ingrid Katz into a treatment for multiple sclerosis at the University of Edmonton. In 2003, he was instrumental in obtaining the financing required to receive Health Canada approval for advancing this research through phase II human clinical trials. [6] The trials received FDA fast track approval in 2008. [7]

Besler is involved in philanthropic and volunteer work for several Canadian charitable organizations.

Medical research

Besler's fundraising has financed areas of medical research including, scleroderma, diabetes, cardiovascular disease, prostate cancer, breast cancer and multiple sclerosis. He has directed his support towards researchers with promising results who no longer are receiving research grants from charitable organizations. "It is surprising to the public that most advanced research into treatments for serious illnesses is not funded by charities nor governments. Private investors are often the only source available to companies seeking to cover the enormous funding costs associated with clinical trials." Besler has stated. [8]

Investment advise

Besler has authored several books on finance and investment including "The PEARL Approach - Protected Effective Asset Risk Limitation investment strategy" and "Investment Advisor Training Guide". [9] In addition, Besler was a featured columnist in "Canadian Money Saver" with Morris I. Bubbis. [10] In 2012, Besler became the most widely read feature columnist for "The Northern Miner" newspaper [11] and "Mining Markets" magazine. [12]

Related Research Articles

Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS), a 501(c)(3) charitable organization founded in 1949, is the largest voluntary health organization dedicated to fighting blood cancer in the world. The LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

Multiple Sclerosis Society of Great Britain

The Multiple Sclerosis Society is the UK's largest charity for people affected by multiple sclerosis (MS). Based in London, it has offices and local groups in England, Northern Ireland, Scotland and Wales. It gained charitable company status in 2010.

Nabilone

Nabilone, sold under the brand name Cesamet among others, is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It mimics tetrahydrocannabinol (THC), the primary psychoactive compound found naturally occurring in Cannabis.

Medical research Wide array of research

Medical research, also known as experimental medicine, encompasses a wide array of research, extending from "basic research", – involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials. Within this spectrum is applied research, or translational research, conducted to expand knowledge in the field of medicine.

An academic clinical trial is a clinical trial not funded by pharmaceutical or biotechnology company for commercial ends but by public-good agencies to advance medicine. These trials are a valuable component of the health care system; they benefit patients and help determine the safety and efficacy of drugs and devices, and play an important role in the checks and balances that regular commercially oriented clinical trials.

The Canadian Cancer Society is Canada's largest national cancer charity and the largest national charitable funder of cancer research in Canada.

The National Multiple Sclerosis Society (NMSS) is a non-profit organization based in New York City with chapters located throughout the United States. The organization funds research, advocates for social and political change, provides education, and sponsors services that help people with multiple sclerosis and their families.

Dr. A. M. James Shapiro is a British-Canadian surgeon best known for leading the clinical team that developed the Edmonton Protocol – an islet transplant procedure for the treatment of type 1 diabetes. Dr. Shapiro is Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and the Director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Program with Alberta Health Services.

European Organisation for Research and Treatment of Cancer

The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.

Nancy Fern Olivieri is a prominent Toronto haematologist and researcher with an interest in the treatment of haemoglobinopathies. She is best known for a protracted struggle with the Hospital for Sick Children and the pharmaceutical company Apotex about the drug deferiprone.

Eva Feldman American neurologist

Eva Lucille Feldman, M.D., Ph.D., F.A.A.N., F.A.N.A. is an American physician and the Russell N. DeJong Professor of Neurology at the University of Michigan. She is the Director of the NeuroNetwork for Emerging Therapies and Director of the University of Michigan ALS Center of Excellence, which includes the Pranger ALS Clinic. She is annually listed in Best Doctors in America, is a Past President of the Peripheral Nerve Society and the American Neurological Association, and a member of the National Academy of Medicine and Association of American Physicians.

Dirucotide

Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids is

The Myelin Repair Foundation (MRF) is a 501(c)3 not-for-profit organization based in Saratoga, California. The organization applies a collaborative business model to the process of medical research with the aim of accelerating the identification and development of new patient treatments. MRF's goal is to license its first drug target for commercial drug development by July 1, 2009, five years after the organization began funding research.

Biovista Inc. is a private drug development services company based in Charlottesville, Virginia, US. Biovista's core business activities include drug repositioning and drug de-risking as well as disease cohort analysis, adverse event prediction and clinical hold analysis services. Biovista is also applying its technology platform to develop its own drug repositioning programs in the areas of central nervous system (CNS), diabetes/obesity, eye disorders, and oncology.

Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners. He is an active private investor and has been working in private equity since 1980. Jon regularly writes, broadcasts and speaks on corporate finance and financial matters. His career has also included spells running Citicorp Venture Capital, Schroder Ventures (Permira) and the buy-out group of Apax, as well as being a director of numerous public and private companies.

Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.

Chronic cerebrospinal venous insufficiency controversy

Chronic cerebrospinal venous insufficiency is a term invented by Italian researcher Paolo Zamboni in 2008 to describe compromised flow of blood in the veins draining the central nervous system. Zamboni hypothesized that it might play a role in the cause or development of multiple sclerosis (MS). Zamboni also devised a surgical procedure which the media nicknamed a liberation procedure or liberation therapy, involving venoplasty or stenting of certain veins. Zamboni's ideas about CCSVI are very controversial, with significantly more detractors than supporters, and any treatments based on his ideas are considered experimental.

Acorda Therapeutics

Acorda Therapeutics, Inc. is an American biotechnology company based in Ardsley, New York. The company develops therapies that improve neurological function in people with Parkinson’s disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.

The Faculty of Medicine and Dentistry at University of Alberta is located in Edmonton, Alberta, Canada. Established in 1913, it is one of the oldest medical schools in Western Canada and is composed of 21 departments, two stand-alone divisions, 9 research groups, and 24 research centers and institutes. Educational, clinical and research activities are conducted in 29 buildings on or near the University of Alberta north campus.

Siponimod

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.

References

  1. ↑ Vasogen Inc., http://www.intellipharmaceutics.com/history.cfm, BioMS Medical Inc. http://www.medwellcapital.com/, Protox Therapeutics http://www.protoxtherapeutics.com/about-overview.php, Hemosol Biopharma Inc. http://www.therapurebio.com/PageContent/Default.aspx?SectionID=2&SectionHeadlineID=3
  2. ↑ Federal Scientific Activities, Copyright Statistics Canada Ministry of Industry, ref. National Research Council (Canada), Catalogue No. 88-204-XPB ISSN   0824-0310 1988
  3. ↑ University of Waterloo Alumni Directory, Second Edition 1990, Office of Alumni Affairs pg. 1:31
  4. ↑ Bank of America Merrill Lynch Canada http://gmi.ml.com/ca/
  5. ↑ The Center For Reproductive Medicine and Infertility (CRMI) http://www.ivf.org, Dr. Kangpu Xu, JAMA 281: 1701-1706
  6. ↑ Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada Multiple Sclerosis, Vol. 14, No. 7, 872-879 (2008) doi : 10.1177/1352458508089226
  7. ↑ http://clinicaltrials.gov, "A Study for Patients With Relapsing Remitting Multiple Sclerosis (MINDSET01)" Eli Lilly and Company, Trial Identifier NCT00869986
  8. ↑ Ben Leeson (May 13, 2005). "Firm To Invest In Secondary Industry In North". The Daily Press. p. A8.
  9. ↑ Government of Canada, Canadian Intellectual Property Office, http://www.cipo.ic.gc.ca reference 1046614
  10. ↑ "Mining the Market", Morris I. Bubbis, Central Publishing, Ottawa ISBN   0-9690443-0-5
  11. ↑ Northern Miner, http://www.northernminer.com/
  12. ↑ Mining Markets, http://www.miningmarkets.ca/
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.